SCHEMBL2360291

SCHEMBL2360291

C=CCc1cccc2sc(S)nc12

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 4/20 0.32
IDO1 P14902 1/20 0.32
LMNA P02545 3/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
AKR1B1 P15121 1/20 0.31
PKM P14618 1/20 0.30
PDPK1 O15530 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11160365 0.81 SMN1; SMN2 (0.36) MEN1KMT2AL3MBTL1ALDH1A1IDO1
SCHEMBL2360344 0.81 GABRA1 (0.46) GABRA1GABRB2MEN1KMT2AL3MBTL1
SCHEMBL3798167 0.81 GABRA1 (0.39) GABRA1GABRB2MEN1KMT2AL3MBTL1
SCHEMBL28532339 0.81 GABRA1 (0.39) GABRA1GABRB2MEN1KMT2AL3MBTL1
SCHEMBL9412069 0.81 ALDH1A1 (0.51) GABRA1GABRB2MEN1KMT2AL3MBTL1
SCHEMBL4740097 0.79
SCHEMBL3655840 0.78 GABRA1 (0.40) GABRA1GABRB2MEN1KMT2AL3MBTL1
SCHEMBL1771923 0.78 MEN1 (0.50) GABRA1GABRB2MEN1KMT2AALDH1A1
SCHEMBL8975933 0.78 MEN1 (0.38) MEN1KMT2AALDH1A1IDO1LMNA
SCHEMBL11808159 0.77 GABRA1 (0.36) GABRA1GABRB2MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120295930-A1 NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE MYLAN LABORATORIES LIMITED (IN) 2012-11-22 US claimed
WO-2011095987-A1 NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE MATRIX LABORATORIES LTD. (IN) 2011-08-11 WO claimed
EP-1858841-B1 COMPOSITION FOR STERILIZATION COMPRISING OMEGA-ALKOXYPEROXYCARBOXYLIC ACID FUJIFILM CORP (JP) 2014-11-26 EP disclosed
US-20120295930-A1 NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE MYLAN LABORATORIES LIMITED (IN) 2012-11-22 US disclosed
WO-2011095987-A1 NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE MATRIX LABORATORIES LTD. (IN) 2011-08-11 WO disclosed
US-7666354-B2 Composition for sterilization comprising ω-alkoxyperoxycarboxylic acid FUJIFILM CORPORATION (JP) 2010-02-23 US disclosed
EP-1858841-A4 COMPOSITION FOR STERILIZATION COMPRISING w-ALKOXYPEROXYCARBOXYLIC ACID FUJIFILM CORP (JP) 2009-03-18 EP disclosed
US-20080009549-A1 Composition for Sterilization Comprising W-Alkoxyperoxycarboxylic Acid FUJIFILM CORPORATION (JP) 2008-01-10 US disclosed
EP-1858841-A2 COMPOSITION FOR STERILIZATION COMPRISING w-ALKOXYPEROXYCARBOXYLIC ACID FUJIFILM Corporation (JP) 2007-11-28 EP disclosed
US-20070179193-A1 Method for preparing aqueous composition for sterilization FUJIFILM CORPORATION (JP) 2007-08-02 US disclosed
EP-1803350-A2 Method for preparing aqueous composition for sterilization Fujifilm Corporation (JP) 2007-07-04 EP disclosed
WO-2006068306-A2 COMPOSITION FOR STERILIZATION COMPRISING ω-ALKOXYPEROXYCARBOXYLIC ACID FUJIFILM CORPORATION (JP) 2006-06-29 WO disclosed
EP-0854168-B1 Rubber composition BRIDGESTONE CORP (JP) 2003-04-02 EP disclosed
EP-0957683-A4 HYDROGEN PEROXIDE DISINFECTING AND STERILIZING COMPOSITIONS METREX RES CORP (US) 2002-05-15 EP disclosed
US-20020010283-A1 RUBBER COMPOSITION BRIDGESTONE CORPORATION (JP) 2002-01-24 US disclosed
EP-0957683-A1 HYDROGEN PEROXIDE DISINFECTING AND STERILIZING COMPOSITIONS Metrex Research Corporation (US) 1999-11-24 EP disclosed
US-5900256-A AQUEOUS, CORROSION RESISTANCE COTTRELL, LTD. (US) 1999-05-04 US disclosed
EP-0854168-A1 Rubber composition Bridgestone Corporation (JP) 1998-07-22 EP disclosed
WO-1998011777-A1 HYDROGEN PEROXIDE DISINFECTING AND STERILIZING COMPOSITIONS COTTRELL, LTD. (US) 1998-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009549-A1 Composition for Sterilization Comprising W-Alkoxyperoxycarboxylic Acid OGDH, OXGR1, AKR1C3 GABRA1 848/4885GABRB2 1153/4885MEN1 1894/4885
US-20070179193-A1 Method for preparing aqueous composition for sterilization CYP19A1, OGDH, SDHB GABRA1 1368/4885GABRB2 1504/4885MEN1 2012/4885
US-20120295930-A1 NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE DDX1, NSUN2, SLC29A1 GABRA1 4660/4885GABRB2 4597/4885MEN1 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.